Stockreport

I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea

I-MAB - American Depositary Shares  (IMAB) 
PDF -The clinical study will explore the potential of TJM2, an anti-GM-CSF monoclonal antibody, to treat cytokine release syndrome in severe and critically ill patients with [Read more]